Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
345
resultados
Última actualización
04/11/2026 [08:50:00]
Resultados 125 a 150 de 345
Resumen de: US20260309671A1
Various examples are provided related to electrochemical biosensors, systems, and methods of use. A biomarker associated with a disease in a biological fluid sample can be detected by first contacting the biological fluid sample with a working electrode of an electrochemical biosensor. Next, one or more changes in an electronic property of the working electrode resulting from binding of the biomarker to the capture agent can be detected. Then, electrochemical data can be determined based at least in part on the one or more changes in the electronic property of the working electrode detected by the electrochemical biosensor. The electrochemical data can then be input into a machine-learning (ML) model trained to analyze the electrochemical data to determine a risk level associated with the disease. Finally, the risk level associated with the disease can be determined based at least in part on the ML model.
Resumen de: US20260309703A1
The present disclosure describes a diagnostic platform that combines CRISPR/Cas technology with electrochemiluminescence (ECL) or fluorescence detection for highly sensitive and specific identification of disease biomarkers, such as microRNAs and proteins, without the need for complex amplification processes.
Resumen de: WO2026209595A1
The present invention is directed to means for assessing whether a subject in need of an anti-amyloid therapy has or develops Amyloid- Related Imaging Abnormality - Edema (ARIA-E) by determining an amount or a concentration of one or more of the following biomarkers CD14, ACE2, MYOC, DCN, CTRC, MERTK, HMOX1, TNR, DKK3, SCGN, L1CAM, LPL, C1QA, F3, NPY, LEP, PGF, TEK, SPP1, and STREM2 in a sample of the subject. Further, the present invention relates to the use of one or more of the following biomarkers CD14, ACE2, MYOC, DCN, CTRC, MERTK, HMOX1, TNR, DKK3, SCGN, L1CAM, LPL, C1QA, F3, NPY, LEP, PGF, TEK, SPP1, and STREM2 in the detection of ARIA-E.
Resumen de: WO2026213448A1
Methods are provided for the high yield and low-cost manufacture of highly pure tau proteins for use as substrates for tau seed amplification assays.
Resumen de: WO2026213047A1
Described herein are methods for analyzing microRNAs (miRNAs) derived from a population of extracellular vesicles (EVs) in a biological sample using next generation sequencing (NGS). The methods comprise isolating the population of EVs from a biological sample obtained from a subject, extracting RNA from the population of EVs, wherein the extracted RNA comprises one or more miRNAs, ligating one or more adapters to the extracted RNA to generate adapter-ligated RNA molecules, reverse transcribing the adapter-ligated RNA molecules to generate a complementary DNA (cDNA) library, amplifying the cDNA library, sequencing the amplified cDNA library using NGS to obtain sequencing reads, and analyzing the sequencing reads by a bioinformatic workflow.
Resumen de: US20260306430A1
Compositions, kits, and methods are disclosed for nutritional neurometabolic support and improved gut health using bioidentical D-beta-hydroxybutyric acid (D-BHB) to promote neurological wellness, mood stability and adaptive brain function during everyday life and during changes in neurologically acting medication regimens. The compositions comprise a salt-free, ester-free, alcohol-free D-BHB acid formulation optionally configured with vitamin B to raise circulating ketone levels, supply a preferred brain energy substrate, and support intestinal barrier integrity by improving tight junction function and reducing paracellular leakiness, thereby influencing gut-brain axis signaling. The compositions optionally incorporate B vitamins with vitamin B6 being a preferred embodiment to complement bioidentical D-BHB by supporting neurotransmitter synthesis and related gut-brain pathways. Kit (701) provides unit dose containers of bioidentical D-BHB, with or without B-vitamin supplementation and optional tapered pharmaceutical doses, together with optional software or AI-based tools configured to capture diet and mood data via smartphone and to generate guidance for nutritional and medication-taper support.
Resumen de: WO2026209799A1
The present application discloses a method of monitoring and/or determining the responsiveness of a subject's eye having capillary retinal perfusion dysfunction, to an administration of a first dose of Annexin A5 to the subject, wherein the method comprises assessing the health of the eye and/or assessing total plasma concentration of phosphatidylserine (PS) at about or within a week, 6 days, 5 days, 4 days, 3 days, 2 days or 1 day, of the administration of the first dose of the Annexin A5 to the subject. These methods permit the rapid stratification of subjects into appropriate treatment groups, and the early onset of a treatment regime that is therapeutically appropriate to the subject.
Resumen de: WO2026211690A1
The present invention addresses the problem of providing a method, a kit, and a biomarker for assisting diagnosis of schizophrenia or depression, and providing a method, a kit, and a biomarker for assisting differentiation from schizophrenia or depression. The present invention provides a method for assisting diagnosis of schizophrenia or depression, wherein the method comprises detecting cells having MS4A3 contained in a test sample.
Resumen de: WO2026212310A1
The present invention relates to a degenerative brain disease model and a method for constructing same and, more specifically, to a disease modeling technology for reproducing non-genetic (sporadic) Alzheimer's disease and cerebral amyloid angiopathy (CAA), which account for the majority of actual patients on the basis of a V-NAMO platform without relying on genetic mutations. Through a combined exposure strategy of amyloid beta oligomers in consideration of the characteristics of a scaffold, pathology in which amyloid plaques accumulate along actual vascular walls and the neurovascular unit is damaged is precisely implemented in vitro, thereby providing an innovative platform for research on mechanisms of degenerative brain diseases and preclinical efficacy evaluation of new drug candidates.
Resumen de: US20260308202A1
Described herein are peptides and pharmaceutical compositions, e.g., for the treatment of inflammation. Further described herein are methods of treating patients for inflammation and/or infection with particularly efficacious treatments depending on the subject's level of fVEGF.
Resumen de: EP4818330A1
The present invention relates to the field of biomedicine. Provided are a marker that can be used for early diagnosis of Alzheimer's disease, and the use thereof. Specifically provided is a marker for early diagnosis of Alzheimer's disease. The marker is a Maf1 gene or the protein rhereof. High expression of the Maf1 gene or the protein thereof in neuronal cells indicates that a subject is at high risk of developing Alzheimer's disease. The method provides a new diagnostic and therapeutic target for AD.
Resumen de: EP4818331A2
0001 The disclosure describes changes in cfRNA gene expression that are associated with risk for preeclampsia. Accordingly, the disclosure provides methods and kits for preeclampsia risk assessment.
Resumen de: GB2705330A
An ink for a screen-printed electrode comprises gold microstructures with a maximum dimension of 0.05-7.5 microns and a polymer dissolved or dispersed in one or more solvents having a boiling point of >110C. The ink may comprise 7.5-25 wt.% gold microstructures, 4-15 wt.% polymer, and 45-65 wt.% solvent. The gold microstructures may be microspheres or microflakes. The polymer may comprise polyethylene terephthalate, polyethyloxazoline, polymethylmethacrylate, polyacrylates, polyesters, polyamines, polyethers, polyvinyl acetate, polyvinyl chloride, polyhydroxyethers, cellulose derivatives, or poly(lactide). The solvent may be alpha-terpineol, di(propylene glycol) methyl ether, or propylene glycol monomethyl ether acetate. A method of making an electrode comprises screen-printing a working electrode onto a substrate using the ink and providing reference and counter electrodes on the substrate. A method of detecting a target analyte in a sample comprises contacting the electrode with the sample, wherein a response characteristic of the electrode is capable of being operably varied, thereby indicating the presence of the analyte. No Figure
Resumen de: JP2026158933A
【課題】皮膚における血管周囲のマクロファージの性質、及び当該マクロファージが血管や皮膚性状に与える影響を明らかにし、新規作用機序に基づく有用な製剤を提供することを課題とする。【解決手段】本発明者らは、誠意研究の結果、皮膚において、毛細血管周囲にＭ２マクロファージが取り囲むように存在すること、Ｍ２マクロファージの培養上清を、血管内皮細胞に添加すると、血管安定化が促進することを発見した。そこで、Ｍ２マクロファージ分化誘導を促進する化粧料素材を探索し、アカツメクサ花エキス、モモ葉エキス、及びアセロラ種子エキスからなる群から選ばれる１又は複数のエキスを含む、Ｍ２マクロファージ分化誘導促進剤、Ｍ２マクロファージ分化誘導促進を介した血管安定化剤、Ｍ２マクロファージ分化誘導促進を介した美白剤を提供する。【選択図】図４
Resumen de: US20260224206A1
0000 An excrement analysis apparatus includes an inputter, a memory, a first analyzer, and a second analyzer. The inputter inputs imaging data captured by an image capture apparatus installed in such a way as to include, in a capturing range, an excretion range of excrement in a toilet bowl of a toilet. The memory temporarily holds the imaging data input by the inputter. The first analyzer analyzes first analysis target data being the imaging data input by the inputter, and outputs notification information to an observer who observes a user of the toilet. The second analyzer analyzes second analysis target data being the imaging data that is input by the inputter and temporarily held by the memory, and outputs detailed information indicating a content of excretion.
Resumen de: JP2026156851A
【課題】 本開示は、ＧＤＦ－１５に対する優れた結合能を有する核酸分子を提供する。【解決手段】 本開示のＧＤＦ－１５結合核酸分子は、（ａ１）配列番号７の塩基配列を含み、且つ、ＧＤＦ－１５に結合するポリヌクレオチド、（ａ２）配列番号７の塩基配列において１若しくは数個の塩基が欠失、置換、挿入、及び／又は付加された塩基配列を含み、且つ、ＧＤＦ－１５に結合するポリヌクレオチド、又は（ａ３）配列番号７の塩基配列に対して８０％以上の同一性を有する塩基配列を含み、且つ、ＧＤＦ－１５に結合するポリヌクレオチドを含み、配列番号７の塩基配列において下線で示されるＴは、チミン塩基又は修飾チミン塩基である。【選択図】 図９
Resumen de: AU2019306121A1
Disclosed herein are methods for treating patients that may develop or already have pre- existing gene therapy neutralizing antibodies by administering a protease that cleaves peptide bonds present in immunoglobulins or by administering a glycosidase that cleaves carbohydrate residues present on immunoglobulins, or other similar enzymatic cleavage of immunoglobulins in vivo. Also disclosed are methods for utilizing IdeS and other immunoglobulin G-degrading enzyme polypeptides for gene therapy treatment of a disease in a patient in need thereof.
Resumen de: WO2025059015A1
Described herein is a system comprising a eukaryotic cell, wherein the eukaryotic cell comprises: a plasma membrane polypeptide coupled to a transcription factor by a linker, wherein the linker comprises a protease cleavable site; and a plasma membrane anchored protease; wherein the plasma membrane anchored protease is capable of cleaving the linker. The system can further include a reporter construct, wherein the transcription factor can bind to a promoter of the reporter construct to indicate an ability of the plasma membrane polypeptide to traffic to the plasma membrane.
Resumen de: MX2026009889A
The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
Resumen de: AU2019205489A1
This invention generally pertains to antibodies and antigen-binding fragments thereof, e.g., humanized, chimeric, and human antibodies and antigen-binding fragments thereof, and fusion proteins, compositions containing such antibodies and antigen-binding fragments thereof and fusion proteins, wherein such antibodies and antigen-binding fragments thereof and fusion proteins specifically bind to MCT1, e.g., human or non-human MCT1 and antagonize, inhibit or block one or more MCT1-associated functions
Resumen de: WO2026199817A1
The present application provides a method for preparing a humanized Aβ1-40 antibody and use thereof. Specifically, the antibody of the present application combines a murine antibody variable region and a human antibody framework region; on the basis of specifically binding to an Aβ peptide segment, the antibody reduces immunogenicity due to its humanized framework region. The antibody has the advantages of high affinity, high specificity, low immunogenicity, and scalability for large-scale production. The antibody of the present application can be used for detecting an Aβ1-40 antigen, eliminating Aβ deposits, or treating related diseases thereof, such as Alzheimer's disease.
Resumen de: CN122872563A
0001 本公开属于生物医药领域，具体涉及靶向TSLP和IL‑4/IL‑4R的双功能融合蛋白及其应用。本公开的双功能融合蛋白对IL‑4R、IL‑4和/或TSLP具有较好的亲和力和/或生物学活性，可用于检测IL‑4R、IL‑4和/或TSLP、诊断或防治与IL‑4R、IL‑4和/或TSLP相关的疾病或病症。
Resumen de: WO2026199818A1
The present application provides a method for preparing a humanized Aβ1-42 antibody and use thereof. Specifically, the antibody of the present application combines a murine antibody variable region and a human antibody framework region; on the basis of specifically binding to an Aβ peptide segment, the antibody reduces immunogenicity due to its humanized framework region. The antibody has the advantages of high affinity, high specificity, low immunogenicity, and scalability for large-scale production. The antibody of the present application can be used for detecting an Aβ1-42 antigen, eliminating Aβ deposits, or treating related diseases thereof, such as Alzheimer's disease.
Resumen de: CN122849250A
0001 本发明公开了一种验证吴茱萸碱改善D‑gal诱导衰老认知及运动功能障碍的方法，属于医学方法验证技术领域。选择雄性小鼠，并分为对照组、D‑半乳糖模型组、DFMO干预组、吴茱萸碱干预组；进行新行为学测试后处理小鼠；分别取每组小鼠眼球血进行血清生化检测；采集组织样本，采用BCA法测定蛋白浓度后，再进行免疫组织化学与免疫荧光测试，而后再进行代谢物检测；培养、处理细胞后进行siRNA转染，进行分子对接评估吴茱萸碱与ODC1的结合能力及相互作用模式；最后分析统计结果。本发明发现吴茱萸碱可显著改善衰老小鼠认知和运动功能障碍，降低脑组织尿素水平，下调尿素循环关键酶表达，抑制P53表达。
Nº publicación: US20260298949A1 01/10/2026
Solicitante:
BECKMAN COULTER INC [US]
BECKMAN COULTER, INC.
Resumen de: US20260298949A1
0000 Disclosed and claimed are compositions containing a calibrator and a stabilizer, wherein the stabilizer includes Diethylaminoethyl-(“DEAE”) dextran; D-Sorbitol, wherein the D-Sorbitol and DEAE-dextran are in a weight ratio from about 1:1 to about 5:2, a buffer; and a non-ionic surfactant; wherein the stabilizer is essentially free of bovine serum albumin; and wherein the calibrator is stabilized under frozen storage conditions, and remains stable when thawed and kept at temperatures of from about 2° C. to about 10° C. Also disclosed are methods of use of the claimed compositions and kits comprising the claimed compositions.
BOPI
Sede Electrónica
